CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

PHASE2RecruitingINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

December 31, 2027

Conditions
Epithelial Ovarian CancerPrimary PeritonealFallopian Tube CancerEndometrioid Ovarian Cancer
Interventions
DRUG

TORL-1-23

2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle.

DRUG

TORL-1-23

3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

DRUG

TORL-1-23

3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

DRUG

Pegfilgrastim (drug)

6.0 mg subcutaneous injection on Day 4 of each cycle.

Trial Locations (42)

2148

RECRUITING

Blacktown Hospital, Blacktown

3000

RECRUITING

UZ Leuven, Leuven

5042

RECRUITING

Flinders Medical Centre, Bedford Park

6020

RECRUITING

Universitatsklinik Innsbruck, Innsbruck

18901

RECRUITING

SCRI - Alliance Cancer Specialists, PC, Doylestown

20159

RECRUITING

Humanitas San Pio X, Milan

21401

RECRUITING

SCRI - Maryland Oncology Hematology, P.A., Annapolis

23502

RECRUITING

SCRI - Virginia Oncology Associates, Norfolk

27710

RECRUITING

Duke Cancer Center, Durham

30322

RECRUITING

Winship Cancer Institute, Emory University, Atlanta

32224

RECRUITING

Mayo Clinic Florida, Jacksonville

43210

RECRUITING

The James Cancer Hospital and Solove Research Institute - Ohio State University, Columbus

55404

RECRUITING

SCRI - Minnesota Oncology Hematology, P.A., Minneapolis

RECRUITING

University of Minnesota, Minneapolis

55905

RECRUITING

Mayo Clinic, Rochester

60637

RECRUITING

University of Chicago Medical Center, Chicago

63108

RECRUITING

Washington University, St Louis

73104

RECRUITING

Stephenson Cancer Center at the University of Oklahoma, Oklahoma City

76104

RECRUITING

SCRI - Texas Oncology, Fort Worth

85054

RECRUITING

Mayo Clinic Hospital, Phoenix

85711

RECRUITING

SCRI - Arizona Oncology Associates, PC-HOPE, Tucson

90095

RECRUITING

UCLA - JCCC Clinical Research Unit, Los Angeles

91010

RECRUITING

City of Hope National Medical Center, Duarte

93105

RECRUITING

SCRI - Sansum Clinic, Santa Barbara

97227

RECRUITING

SCRI - Northwest Cancer Specialists, P.C., Portland

119074

RECRUITING

National University Cancer Institute, Singapore

168583

RECRUITING

National Cancer Centre, Singapore

217562

RECRUITING

Curie Oncology (Farrer), Singapore

06510

RECRUITING

Smilow Cancer Hospital at Yale - New Haven, New Haven

02114

RECRUITING

Massachusetts General Hospital, Boston

08901

RECRUITING

Rutgers Cancer Institute, New Brunswick

19104-4238

RECRUITING

University of Pennsylvania, Philadelphia

VIC 3168

RECRUITING

Monash Medical Centre, Clayton

QLD 4032

RECRUITING

Icon Cancer Centre Chermside, Chermside

WA 6009

RECRUITING

Linear Clinical Research, Perth

V5Z 4E6

RECRUITING

British Columbia Cancer Agency (BC Cancer, part of the Provincial Health Services Authority), Vancouver

M4N 3M5

RECRUITING

Sunnybrook Research Institute, Toronto

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre - University Health Network (UHN), Toronto

H2X 0C2

RECRUITING

Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal

H3T 1E2

RECRUITING

Sir Mortimer B. Davis Jewish General Hospital, Montreal

H4A 3J1

RECRUITING

McGill University Health Centre (MUHC) - Royal Victoria Hospital, Montreal

D07 R2WY

RECRUITING

Start Dublin - Mater Misericordiae University Hospital, Dublin

All Listed Sponsors
collaborator

European Network of Gynaecological Oncological Trial Groups (ENGOT)

OTHER

lead

TORL Biotherapeutics, LLC

INDUSTRY